Adriamycin (ADM) was encapsulated in multivesicular lipasomes which composed of lipids of eggs origin. The chemothera-peutic activity of the encapsulated ADM was compared with that of free ADM at equal doses in micc bearing SRS lymphoma. The results showed that encapsulation of ADM into lipo-somes resulting in markedly increased efficacy than free ADM. At the dose of 1 mg?kg-1 (every 24 h for 3 separate intraperitoneal injections) , free ADM and ADM entrapped intolipasomes with the same dose had 1. 5 times and 3 times increase the survival time of SRS lymphoma mice respectively as compared with that of the control. The curative rate of mice treated by liposome ADM was 100% on 30 days and 60% on 60 days. The results of LD50 determination showed that the acute toxicity of mice treated by liposome ADM was much less than that of the mice treated with free ADM.